The papers worth your time, checked against the source.
NeuroBrief is for neurologists, neuroscientists, and the clinicians beside them. We gather the new literature, re-check the claims against the primary paper, and write what actually changed — including what the study does not show.
Each of these is an EXAMPLE. The format is the product. The studies are not real and should not be cited.
Method
Curation is not the same thing as verification.
01
Gather
New papers, journal issues, and public notices go into a review queue. PubMed and a few journal feeds can be pulled in for an editor. Nothing in that queue is published.
02
Re-check
An editor opens the primary paper, preprint, or official notice and compares the claim with what the source actually reports: cohort, endpoint, numbers, and the limit of the result.
03
Sign
The briefing names its sources and the date it was verified. If the source is later corrected, the piece is updated and marked corrected. Pending means it is not signed.
What verification means here
The claim matches the source’s own conclusion
Population, sample size, and endpoint are stated
An effect is not rewritten as clinical advice
Funding and conflicts are noted when the source states them
Preprints, corrections, and retractions stay labeled
The verified-on date is the day an editor signed, not the day a press release landed
Readers
Written for people who already read the literature.
Clinical neurologists
A short, sourced account of what changed, readable before clinic, with the caveat still attached.
Neuroscientists
Adjacent fields, without pretending a single paper settled them. Methods and limits stay in the piece.
Fellows and research staff
The citation, the endpoint, and what the study does not show — not a rewrite of the embargoed quote.
Pricing
One subscription. The whole briefing.
No seats, no annual upsell, no second tier. twice a week in the live service. Cancel whenever you like.
NeuroBrief
$10per month
Every published briefing, in full
Primary sources linked on each piece
Verification status and the date an editor signed
The archive of briefings published so far
A billing portal to update a card or cancel, once Stripe is connected
A fictional screen says a kinase inhibitor slowed growth in some patient-derived glioma organoids and not others. The example refuses to call that a treatment result. Not a real screen.
A made-up cohort study claims a four-protein blood panel tracked amyloid PET in people without symptoms. This example shows how a briefing would separate the claim, the design, and the limits. It is not a real study.
A fictional randomized trial reports a benefit for thrombectomy out to 24 hours in a narrowly selected group. The example briefing keeps the imaging criteria beside the headline result. Not a real trial.